EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Cardio‐renal‐metabolic disease in primary care setting

Mahmoud Ibrahim iD, Ebtesam M Ba-Essa iD, Jason Baker iD, Avivit Cahn iD, Antonio Ceriello iD, Francesco Cosentino iD, Melanie J Davies iD, Robert H Eckel iD, Luc Van Gaal, Peter Gaede iD, Yehuda Handelsman iD, Samuel Klein iD und 11 weitere

Diabetes/Metabolism Research and Reviews · 2024

DOI: 10.1002/dmrr.3755 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes/Metabolism Research and Reviews, 2024. Verfasst von Mahmoud Ibrahim und 22 weiteren Autor:innen. Beteiligte Einrichtung: EDC, Centre for Diabetes Education, Charlotte, North Carolina, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Heart Diseases, Cardiovascular Diseases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 188 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the primary care setting providers have more tools available than ever before to impact positively obesity, diabetes, and their complications, such as renal and cardiac diseases. It is important to recognise what is available for treatment taking into account diabetes heterogeneity. For those who develop type 2 diabetes (T2DM), effective treatments are available that for the first time have shown a benefit in reducing mortality and macrovascular complications, in addition to the well‐established benefits of glucose control in reducing microvascular complications. Some of the newer medications for treating hyperglycaemia have also a positive impact in reducing heart failure (HF). Technological advances have also contributed to improving the quality of care in patients with diabetes. The use of technology, such as continuous glucose monitoring systems (CGM), has improved significantly glucose and glycated haemoglobin A1c (HbA1c) values, while limiting the frequency of hypoglycaemia. Other technological support derives from the use of predictive algorithms that need to be refined to help predict those subjects who are at great risk of developing the disease and/or its complications, or who may require care by other specialists. In this review we also provide recommendations for the optimal use of the new medications; sodium‐glucose co‐transporter‐2 inhibitors (SGLT2i) and Glucagon‐like peptide‐receptor agonists 1 (GLP1RA) in the primary care setting considering the relevance of these drugs for the management of T2DM also in its early stage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsHeart DiseasesCardiovascular DiseasesHumansHypoglycemic AgentsBlood Glucose Self-MonitoringBlood GlucoseGlucagon-Like Peptide 1Primary Health CareGlucagon-Like Peptide-1 Receptor

Stichwörter der Autor:innen

CVOTschronic kidney diseaseheart failureobesitytechnologytype 2 diabetes

Substanzen

Hypoglycemic AgentsBlood GlucoseSodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor

Autor:innen und Institutionen

  • EDC, Centre for Diabetes Education, Charlotte, North Carolina, USA.
  • Al-Rawdah General Hospital, Dammam, Saudi Arabia.
  • Weill Cornell Medicine, New York, New York, USA.
  • The Diabetes Unit & Endocrinology and Metabolism Unit, Hadassah Hebrew University Hospital, Jerusalem, Israel.
  • IRCCS MultiMedica, Milan, Italy.
  • Unit of Cardiology, Department of Medicine Solna, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.

ORCID-Profile: Mahmoud Ibrahim, Ebtesam M Ba-Essa, Jason Baker, Avivit Cahn, Antonio Ceriello, Francesco Cosentino, Melanie J Davies, Robert H Eckel, Peter Gaede, Yehuda Handelsman, Samuel Klein, Richard David Leslie, Stefano Del Prato, Francesco Prattichizzo, Petar M Seferovic, Eberhard Standl, Abraham Thomas, Jaakko Tuomilehto, Paul Valensi, Guillermo E Umpierrez

Förderung

  • NIDDK NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Ibrahim, M., Ba-Essa, E. M., Baker, J., Cahn, A., Ceriello, A., Cosentino, F., Davies, M. J., Eckel, R. H., Van Gaal, L., Gaede, P., Handelsman, Y., Klein, S., Leslie, R. D., Pozzilli, P., Del Prato, S., Prattichizzo, F., Schnell, O., Seferovic, P. M., Standl, E., …, & Umpierrez, G. E. (2024). Cardio‐renal‐metabolic disease in primary care setting. Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.3755

Vancouver

Ibrahim M, Ba-Essa EM, Baker J, Cahn A, Ceriello A, Cosentino F, et al. Cardio‐renal‐metabolic disease in primary care setting. Diabetes/Metabolism Research and Reviews. 2024. doi:10.1002/dmrr.3755

BibTeX
@article{Ibrahim2024,
  author = {Ibrahim, Mahmoud and Ba-Essa, Ebtesam M and Baker, Jason and Cahn, Avivit and Ceriello, Antonio and Cosentino, Francesco and Davies, Melanie J and Eckel, Robert H and Van Gaal, Luc and Gaede, Peter and Handelsman, Yehuda and Klein, Samuel and Leslie, Richard David and Pozzilli, Paolo and Del Prato, Stefano and Prattichizzo, Francesco and Schnell, Oliver and Seferovic, Petar M and Standl, Eberhard and Thomas, Abraham and Tuomilehto, Jaakko and Valensi, Paul and Umpierrez, Guillermo E},
  title = {Cardio‐renal‐metabolic disease in primary care setting},
  journal = {Diabetes/Metabolism Research and Reviews},
  year = {2024},
  doi = {10.1002/dmrr.3755}
}
Kostenlos starten →